FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to the use of 1,1-dioxo-1,4-dihydro-2H-benzo[1,2,4]thiadiazine-3-one of general formula 1 as inhibitors of the penetration of hepatitis D virus (HDV). Inhibitors block the NTCP receptor of hepatocyte, the activity of which promotes the development of hepatitis D. In general formula 1
, 
Ar1 and Ar2 are optionally identical phenyls optionally substituted with one, two or three substituents selected from C1-C4alkyl, methoxyl, halogen and carbonitrile.
EFFECT: invention also relates to a novel compound 1_7 selected from the group of compounds of general formula 1, which additionally has the properties of an inhibitor of hepatitis B virus (HBV).
8 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HEPATITIS B (HBV) INHIBITOR | 2017 |
|
RU2666727C1 |
| BENZO[1,2,4]THIADIAZINE INHIBITORS OF HEPATITIS B VIRUS REPLICATION AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B | 2015 |
|
RU2574397C1 |
| PANGENOTYPIC NS5A PROTEIN INHIBITOR OF HEPATITIS C VIRUS, A PHARMACEUTICAL COMPOSITION AND METHODS FOR PREPARING AND USING | 2019 |
|
RU2723482C1 |
| HEPATITIS B VIRUS (HBV) INHIBITOR | 2019 |
|
RU2726456C1 |
| HEPATITIS B VIRUS INHIBITOR (HBV) | 2019 |
|
RU2736975C1 |
| CYCLOBUTYL (S)-2-[[[R)-2-(6-AMINOPURIN-9-YL)-1-METHYL-ETOXY]METHYL-PHENOXY-PHOSPHORYL]AMINO]-PROPANOATES, METHOD OF THEIR PRODUCTION AND APPLICATION | 2017 |
|
RU2647576C1 |
| NUCLEOTIDES INCLUDING N-[(S)-1-CYCLOBUTOXYCARBONYL]PHOSPHORAMIDATE FRAGMENT, THEIR ANALOGS AND THEIR APPLICATION | 2017 |
|
RU2659388C1 |
| COMBINED DRUG FOR VIRAL INFECTION THERAPY | 2017 |
|
RU2662160C9 |
| HEPATITIS B VIRUS (HBV) INHIBITOR, WHICH IS A DERIVATIVE OF N-{3-[6-(DIALKYLAMINO)PYRIDAZINE-3-YL]PHENYL}ARYL SULPHONAMIDE DERIVATIVES AND DERIVATIVES OF N-{4-[6-(DIALKYLAMINO)PYRIDAZINE-3-YL]PHENYL}ARYL SULPHONAMIDE | 2019 |
|
RU2738848C1 |
| MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
